Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications? (2017)
- Autor:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1016/j.atherosclerosis.2017.06.004
- Subjects: ARTERIOSCLEROSE; HIPERCOLESTEROLEMIA; ARTÉRIA CARÓTIDA INTERNA; COLESTEROL; CALCIFICAÇÃO FISIOLÓGICA
- Language: Inglês
- Imprenta:
- Source:
- Título: Atherosclerosis
- ISSN: 0021-9150
- Volume/Número/Paginação/Ano: v. 263, p. 316-317, 2017
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SANTOS FILHO, Raul Dias dos. Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications?. Atherosclerosis. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.atherosclerosis.2017.06.004. Acesso em: 23 jan. 2026. , 2017 -
APA
Santos Filho, R. D. dos. (2017). Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications? Atherosclerosis. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.atherosclerosis.2017.06.004 -
NLM
Santos Filho RD dos. Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications? [Internet]. Atherosclerosis. 2017 ; 263 316-317.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2017.06.004 -
Vancouver
Santos Filho RD dos. Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications? [Internet]. Atherosclerosis. 2017 ; 263 316-317.[citado 2026 jan. 23 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2017.06.004 - Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
- Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study
- Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia
- Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study
- Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients
- Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia
- Sodium intake and prevalence of hypertension in elementary school students
- Clinical Genetic Testing for Familial Hypercholesterolemia
- Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab
- Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary
Informações sobre o DOI: 10.1016/j.atherosclerosis.2017.06.004 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
